Pasar al contenido principal

¿EXISTEN SUBTIPOS DE EOSINOFIOS EN HUMANOS?. RELEVANCIA CLINICA EN LA ERA DE LOS NUEVOS TRATAMIENTOS BIOLOGICOS PARA EL ASMA EOSINOFILICA GRAVE

PI21/00896

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2021
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ
Centro realización FUNDACION INSTITUTO DE INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Analysis of Differentially Expressed MicroRNAs in Serum and Lung Tissues from Individuals with Severe Asthma Treated with Oral Glucocorticoids

  • Gil-Martínez, Marta|||0000-0002-2075-7874
  • Lorente-Sorolla, Clara|||0000-0003-0404-9453
  • Rodrigo-Muñoz, José Manuel|||0000-0003-3873-4563
  • Lendínez, Miguel Ángel
  • Núñez-Moreno, Gonzalo|||0000-0001-5982-570X
  • de la Fuente, Lorena
  • Minguez, Pablo|||0000-0003-4099-9421
  • Mahíllo-Fernández, Ignacio|||0000-0003-0558-6541
  • Sastre, Joaquin|||0000-0003-4689-6837
  • Valverde-Monge, Marcela|||0000-0002-0172-3951
  • Quirce Gancedo, Santiago|||0000-0001-8086-0921
  • Caballero, María L.
  • González-Barcala, Francisco-Javier|||0000-0001-5847-4784
  • Arismendi, Ebymar|||0000-0002-7749-2838
  • Bobolea, Irina|||0000-0002-7425-2417
  • Valero, Antonio
  • Muñoz Gall, Francisco Javier|||0000-0002-8693-022X
  • Cruz, María Jesús|||0000-0001-9759-5466
  • Martínez Rivera, Carlos|||0000-0003-1031-2561
  • Plaza, Vicente|||0000-0003-2567-5496
  • Olaguibel, José M.
  • Del Pozo, Victoria|||0000-0001-6228-1969
Nowadays, microRNAs (miRNAs) are increasingly used as biomarkers due to their potential contribution to the diagnosis and targeted treatment of a range of diseases. The aim of the study was to analyze the miRNA expression profiles in serum and lung tissue from patients with severe asthma treated with oral corticosteroids (OCS) and those without OCS treatment. For this purpose, serum and lung tissue miRNAs of OCS and non-OCS asthmatic individuals were evaluated by miRNAs-Seq, and subsequently miRNA validation was performed using RT-qPCR. Additionally, pathway enrichment analysis of deregulated miRNAs was conducted. We observed altered expression by the next-generation sequencing (NGS) of 11 miRNAs in serum, of which five (hsa-miR-148b-3p, hsa-miR-221-5p, hsa-miR-618, hsa-miR-941, and hsa-miR-769-5p) were validated by RT-qPCR, and three miRNAs in lung tissue (hsa-miR-144-3p, hsa-miR-144-5p, and hsa-miR-451a). The best multivariate logistic regression model to differentiate individuals with severe asthma, treated and untreated with OCS, was to combine the serum miRNAs hsa-miR-221-5p and hsa-miR-769-5p. Expression of hsa-miR-148b-3p and hsa-miR-221-5p correlated with FEV/FVC (%) and these altered miRNAs act in key signaling pathways for asthma disease and the regulated expression of some genes (FOXO3, PTEN, and MAPK3) involved in these pathways. In conclusion, there are miRNA profiles differentially expressed in OCS-treated individuals with asthma and could be used as biomarkers of OCS treatment.